Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,001
NCT01222624
PankoMab-GEX™: Phase 1 Dose Escalation Study
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2009
Completion: May 31, 2013
NCT01222637
CetuGEX™: Phase 1 Study in Cancer Patients
Start: Aug 31, 2010
Completion: Oct 31, 2013
NCT01354886
Single Dose FSH-GEX™ in Healthy Volunteers
Start: Apr 30, 2011
Completion: Oct 31, 2011
NCT01409343
TrasGEX™: Phase 1 Study in Cancer Patients
Start: Jul 31, 2011
Completion: Dec 31, 2013
NCT01477073
Multiple Dose FSH-GEX(TM) in Healthy Volunteers
Start: Oct 31, 2011
Completion: May 31, 2012
NCT01794208
Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®
Phase: Phase 2
Start: Jan 8, 2013
Completion: Jul 30, 2013
NCT01899599
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
Start: Sep 30, 2013
Completion: Jul 28, 2017
NCT02052960
CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
Start: Feb 28, 2014
Completion: Oct 4, 2017
NCT03360734
Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors
Start: Nov 2, 2017
Completion: Sep 29, 2020